KR20190012795A - Heated Paeonia lactiflora extract having effect of decreasing the production of advanced glycation end product and composition comprising the same for antioxidant and anti-wrinkle effect - Google Patents

Abstract

The present invention relates to an alcohol-roasted Paeonia lactiflora extract exhibiting a decrease in production of advanced glycation end products (AGEs), and a composition containing the same as an active component for antioxidant and wrinkle reducing effects. Since the alcohol-roasted Paeonia lactiflora extract according to the present invention inhibits the production of AGEs and exhibits antioxidant and wrinkle reducing effects, the alcohol-roasted Paeonia lactiflora extract can be usefully utilized for the development of a pharmaceutical composition, a food composition or a cosmetic composition which exhibits the functionalities.

Description

[TECHNICAL FIELD] The present invention relates to a composition for preventing or inhibiting the formation of endogenous saccharides, and a composition for improving antioxidant and wrinkles containing the same as an active ingredient, wrinkle effect}

The present invention relates to an extract of Chinese cabbage, which shows an inhibitory effect on the formation of advanced glycation end products (AGEs), and a composition for improving antioxidation and wrinkles containing the extract as an active ingredient.

Advanced glycation endproducts (AGEs) refers to a form in which glucose, the reducing sugar, reacts with the free amino group of the protein to form a covalent bond through a non-enzymatic glycation reaction when the sugar in the blood increases, AGEs cause diseases such as cell damage and arteriosclerosis, and are a major cause of skin aging in particular.

 AGEs induce cellular reactive oxygen species (ROS), which accelerate intracellular stress by reducing the activity of glyoxalase and bind to AGEs receptors on the cell surface by reactive oxygen species Reported. The resulting ROS stimulates the production of cytokines and activates the signal transduction system, causing an inflammatory response to the activation of nuclear factor κB (NF-κB) in skin tissue, resulting in collagen reduction, skin cell damage, and skin inflammatory disease . Recently, the intake of antioxidants that prevent oxidative stress has been recommended to prevent the accumulation of AGEs, and there has been much interest in the study of safe natural products.

On the other hand, peony ( Paeonia, lactiflora has been used as a root in Paeoniaceae to treat abdominal pain, analgesia, gynecologic depression, hypertension, and inflammation. Typical ingredients are paeoniflorin, paeonol, peaonin, peaoniflorin. Among the ingredients of peony, paeoniflorin has been shown to have an antioxidant effect, and its pharmacological actions have been reported to have anti-cancer effect and enhancement of immune function.

 Herbal medicines are generally used after drying, cutting, and refining. Medicinal herbs are called medicines that change the original properties of medicines for their intended use or medicinal purposes. They are called " , And "Pseudomonas aeruginosa" (雷公 - 炙 論) are described in various numerical methods and efficacy, toxicity and stability according to fungi.

However, there has been no report on a preparation method for maximizing the pharmacological activity of peanut, which exhibits various physiological activities.

Accordingly, the present inventor has made a careful effort to develop a functional raw material derived from peony root by treating phytophthora with peony root. As a result, it was found that the peony root phytophthora extract has a very excellent effect of inhibiting the final glycoside, And an effect of improving skin wrinkles, and completed the present invention.

Accordingly, it is an object of the present invention to provide a jujube extract of Panax ginseng which inhibits the production of advanced glycation end products and exhibits antioxidant and skin wrinkle-improving effects.

It is another object of the present invention to provide a method for producing the extract of Prunus persica, which comprises extracting the extract with a solvent selected from the group consisting of water, an alcohol having 1 to 6 carbon atoms, hexane, ethyl acetate and a mixed solvent thereof. .

It is another object of the present invention to provide a method for preparing a fermented soybean paste, which comprises preparing a fermented soybean paste by roasting the fermented soybean paste at a temperature of 150 to 250 DEG C for 3 to 15 minutes after soaking the fermented soybean paste in 10 to 70% (v / v) And to provide a jujube extract of peony root.

It is another object of the present invention to provide a composition for antioxidation comprising the above extract of Peony root as an active ingredient.

It is another object of the present invention to provide a food composition for improving wrinkles containing the extract of Alaska pollack as an active ingredient.

It is another object of the present invention to provide a cosmetic composition for improving wrinkles containing the extract of Anguilla japonica as an active ingredient.

In order to achieve the object of the present invention, the present invention provides an extract of Prunus persicae, which inhibits the production of advanced glycation end products and exhibits antioxidative and skin wrinkle-reducing effects.

In order to achieve the object of the present invention, the extract of the present invention is extracted with any one solvent selected from the group consisting of water, an alcohol having 1 to 6 carbon atoms, hexane, ethyl acetate and a mixed solvent thereof.酒 炒) peony extract.

In order to accomplish the object of the present invention, the present invention relates to a method for preparing a fermented soybean curd according to the present invention, wherein the soybean curd is moistened with 10 to 70% (v / v) ethanol and roasted at a temperature of 150 to 250 ° C for 3 to 15 minutes Which is characterized in that it is prepared as described above.

In order to accomplish the object of the present invention, the present invention provides a composition for antioxidation comprising the extract of Peony root as an active ingredient.

In order to accomplish the object of the present invention, the present invention provides a composition for improving wrinkles comprising the extract of Peony root as an active ingredient.

In order to accomplish the object of the present invention, the present invention provides a cosmetic composition for improving wrinkles comprising the extract of Aesculum phlegmonacea as an active ingredient.

Hereinafter, the present invention will be described in more detail.

The present invention provides an extract of Prunus persicae which inhibits the production of advanced glycation end products and exhibits antioxidative and skin wrinkle-reducing effects.

In the present invention, the 炒炒 작 peanut peanut is produced by a method in which the peony root is soaked in 10 to 70% (v / v) ethanol and roasted at a temperature of 150 to 250 째 C for 3 to 15 minutes. Preferably 10 to 60% (v / v) ethanol, more preferably 10 to 50% (v / v) ethanol, most preferably 20 to 40% (v / v) Preferably at a temperature of 150 to 230 ° C, more preferably at a temperature of 170 to 230 ° C, most preferably at a temperature of 180 to 210 ° C, preferably 3 to 12 minutes, more preferably 5 to 20 minutes, 12 minutes, and most preferably 5 to 10 minutes.

In the present invention, the above extract can be produced by a conventional extraction method known in the art, for example, a solvent extraction method. The extraction solvent used in the preparation of the extract using the solvent extraction method includes water, a lower alcohol having 1 to 6 carbon atoms (for example, methanol, ethanol, propanol and butanol), or a lower alcohol, propylene glycol, 1,3 -Butylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane and mixtures thereof, of which water, alcohol or mixtures thereof desirable. When water is used as the extraction solvent, the water is preferably hot water. When an alcohol is used as an extraction solvent, the alcohol is preferably a lower alcohol having 1 to 4 carbon atoms, and the lower alcohol is more preferably selected from methanol or ethanol. When a functional alcohol is used as an extraction solvent, the alcohol content is preferably 40 to 90%, more preferably 40 to 70%.

It is obvious to those skilled in the art that the extract of the present invention can be obtained not only by the above-mentioned extraction solvent but also by using other extraction solvent, which exhibits substantially the same effect. In addition, the extract of the present invention includes not only the extract obtained by the above-mentioned extraction solvent, but also an extract obtained through other conventional extraction methods, an extract obtained through purification and fermentation processes. For example, decompression by carbon dioxide, extraction by supercritical extraction with high temperature, extraction by extraction using ultrasound, separation by ultrafiltration membrane with constant molecular weight cutoff value, various chromatography (size, charge, hydrophobic or affinity And the active fraction obtained through various purification and extraction methods, such as those extracted by fermentation products using natural or various microorganisms, are also included in the extract of the present invention.

According to one embodiment of the present invention, it has been confirmed that the extract of Peony root of Chinese cabbage has an excellent effect of inhibiting the production of the final saccharification product in serum and tissues of experimental animals. As a result, Wrinkle improving activity.

Accordingly, the present invention provides a composition for antioxidation comprising the extract of Aesculus fruticosa as an active ingredient.

In the present invention, the term 'antioxidant' refers to a cell that is caused by oxidative stress caused by intracellular metabolism or ultraviolet rays, and which is highly reactive with a free radical or a reactive oxygen species (ROS) Refers to inhibition of oxidation, and includes removal of free radical or reactive oxygen species, thereby reducing damage to the cells.

In the present invention, the composition for antioxidation is a pharmaceutical composition according to its use. Functional food composition or cosmetic composition.

When the antioxidant composition is in the form of a pharmaceutical composition, it can be used as a composition for preventing or treating diseases caused by oxidative stress.

The present invention also provides a wrinkle-improving food composition or cosmetic composition comprising the extract of Ganoderma Lucidum as an active ingredient.

According to one embodiment of the present invention, it was confirmed that the extract of Codonopsis lanceolata inhibited the expression of MMP-1, which promotes collagen degradation, and thus has an excellent effect of increasing the expression of collagen.

In the present invention, the " pharmaceutical composition " may further contain at least one pharmaceutically acceptable carrier, excipient or diluent in addition to the above-mentioned initial extract of peony root extract of the present invention. The term "pharmaceutically acceptable" as used herein means a non-toxic composition which is physiologically acceptable and which, when administered to humans, does not inhibit the action of the active ingredient and does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, .

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, it may contain various drug delivery materials used for oral administration to peptide preparations. In addition, the carrier for parenteral administration may contain water, a suitable oil, a saline solution, an aqueous glucose and a glycol, and may further contain a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, etc. in addition to the above components. Other pharmaceutically acceptable carriers and preparations can be found in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).

The composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration Lt; / RTI >

The pharmaceutical composition of the present invention can be formulated into oral preparations or parenteral administration preparations according to the administration route as described above.

In the case of a preparation for oral administration, the composition of the present invention may be formulated into a powder, a granule, a tablet, a pill, a sugar, a tablet, a liquid, a gel, a syrup, a slurry, . For example, an oral preparation can be obtained by combining the active ingredient with a solid excipient, then milling it, adding suitable auxiliaries, and then processing the mixture into a granular mixture. Examples of suitable excipients include, but are not limited to, sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose and the like, fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant. Further, the pharmaceutical composition of the present invention may further comprise an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In the case of a preparation for parenteral administration, it can be formulated by a method known in the art in the form of injection, cream, lotion, external ointment, oil, moisturizer, gel, aerosol and nasal aspirate. These formulations are described in Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, Pa., 1995, which is a commonly known formulary for all pharmaceutical chemistries.

 The total effective amount of the composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol administered over a prolonged period of time in multiple doses. In the pharmaceutical composition of the present invention, the content of the active ingredient may be varied depending on the degree of the disease. Preferably, the total preferred dose of the pharmaceutical composition of the present invention may be from about 0.01 μg to 10,000 mg, and most preferably from 0.1 μg to 1000 mg per kg body weight of the patient per day. However, the dosage of the pharmaceutical composition may be determined depending on various factors such as the formulation method, administration route and frequency of treatment, as well as the patient's age, body weight, health condition, sex, severity of disease, diet and excretion rate, It will be possible to determine the appropriate effective dose of the composition of the present invention by those of ordinary skill in the art in view of this point. The pharmaceutical composition according to the present invention is not particularly limited to its formulation, administration route and administration method as long as the effect of the present invention is exhibited.

The term "prevention" as used herein, on the other hand, means any action that inhibits or delays disease by administration of a composition comprising the mixture of the present invention. The term "treatment ", as used herein, refers to any action that improves or alleviates a symptom of a disease upon administration of a composition comprising a mixture of the present invention.

In the present invention, the above-mentioned "food composition" includes all forms such as functional food, nutritional supplement, health food, and food additives. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.

For example, as the health food, the composition itself may be prepared in the form of tea, juice, and drink and then taken for drinking, granulated, encapsulated and powdered. Functional foods also include beverages (including alcoholic beverages), fruits and their processed foods (such as canned fruits, bottled, jam, marmalade, etc.), fish, meats and their processed foods (eg, ham, sausage, Breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), juice, various drinks, cookies, sugar, dairy products such as butter, cheese, edible vegetable oil, margarine, vegetable protein, Frozen foods, various seasonings (eg soybean paste, soy sauce, sauces, etc.), and the like. In order to use the composition of the present invention in the form of a food additive, it may be prepared in the form of a powder or a concentrated liquid.

In the food composition of the present invention, the preferred content of the above extract is from 0.001 to 50%, preferably from 0.1 to 50%, based on the total weight of the food composition.

In the present invention, the above-mentioned " cosmetic composition " can be applied to gel type, skin type, cream type, ointment type and the like, but is not limited thereto. The above composition can be suitably prepared by known methods, adding appropriate conventional softening agents, emulsifying agents, thickening agents or other materials known in the art depending on the type thereof.

The gel-type composition may be prepared by adding a softening agent such as trimethylolpropane, polyethylene glycol or glycerin, a solvent such as propylene glycol, ethanol, isocetyl alcohol, or the like.

The skin-type composition may contain at least one of fatty alcohols such as stearyl alcohol, myristyl alcohol, behenyl alcohol, arachidyl alcohol, isostearyl alcohol and isocetyl alcohol, butylene glycol, 2-sodium, xanthan gum, dimethicone, polyethylene glycol-60 hydrogeneate castor oil, polysorbate 60 and purified water.

The cream-type composition may be formulated by dissolving or dispersing the above-mentioned cream type composition in an aqueous medium such as alcohols such as stearyl alcohol, myristyl alcohol, behenyl alcohol, arachidyl alcohol, isostearyl alcohol, isocetyl alcohol and the like, lecithin, phosphatidylcholine, phosphatidylethanolamine, Emulsifiers such as glyceryl stearate, sorbitan palmitate, and sorbitan stearate; natural fats or oils such as avocado oil, apricot oil, barba water oil, glass fat oil and camellia oil; Propylene glycol and the like, purified water, and the like.

The ointment type composition may be prepared by adding a softening agent, an emulsifying agent, and a wax such as microcrystalline wax, paraffin, ceresin, wax, spermaceti, vaseline or the like.

In the present invention, the cosmetic composition may further contain at least one ingredient which exhibits the same or similar functions in addition to the effective ingredient. Non-limiting examples include, but are not limited to, one or more selected from the group consisting of vitamin C, retinoic acid, TGF, protein from animal placenta, betulinic acid and chlorella extract. The cosmetic composition of the present invention may further contain an excipient including a fluorescent substance, a fungicide, a hygroscopic substance, a moisturizing agent, a fragrance, a fragrance carrier, a protein, a solubilizer, a sugar derivative, a sunscreen, a vitamin, .

The effect of the composition according to the invention is illustrated in the following examples.

The extract of Peony root according to the present invention inhibits the production of the advanced glycation end product, thereby exhibiting antioxidative and anti-wrinkle effects. Therefore, a pharmaceutical composition, a food composition or a cosmetic It can be very usefully utilized in the development of a composition.

FIG. 1 is a graph showing the results of measurement of the amount of serum reactive oxygen (ROS) after administering an extract of Prunus persicae to an animal model in which a final glycosylated product was induced (Nor: normal animal group, Con: control group, PR: Administration group, HPR: primary phytophthora extract group).
FIG. 2 is a graph showing the results of measuring the amount of the final glycation products in the skin tissue after administering the extract of Prunus persicae to the animal model in which the final glycation endogenesis was induced (Nor: normal animal group, Con: control group, PR: Administration group, HPR: primary phytophthora extract group).
FIG. 3 is a graph showing the results of western-blot analysis of the expression of proteins involved in the final glycation endogenesis in renal tissue after administration of the extract of Anthracis powder to the animal model in which the final glycation endogenesis was induced (Nor: normal animal group, Con: Control group, PR: Peony extract group, HPR: Peony root extract group).
FIG. 4 is a graph showing the results of western-blot analysis of the expression of proteins associated with the formation of final glycation end products in skin tissue after administration of the extract of Prunus persicae to the animal model in which the final glycation endogenesis was induced (Nor: Con: Control group, PR: Peony extract group, HPR: Peony root extract group).
FIG. 5 is a graph showing the expression of antioxidative-related proteins Catalase (A) and GPX (B) in skin tissues by western-blotting after administering an extract of Anthracis powder to an animal model in which the final glycation endogenesis was induced Nor: normal animal group, Con: control group, PR: peony extract group, HPR: primary phytophthora extract group).
FIG. 6 is a graph showing the results of western blot analysis of expression of COL1A2 (A) and MMP-1 (B) in skin tissue after administration of an extract of Anthracis powder to an animal model in which a final glycation endogenate was induced (Nor: Con: Control group, PR: Peony extract group, HPR: Peony root extract group).

Hereinafter, the present invention will be described in detail with reference to preferred embodiments. Prior to this, terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms, and the inventor should appropriately interpret the concepts of the terms appropriately The present invention should be construed in accordance with the meaning and concept consistent with the technical idea of the present invention. Accordingly, it is to be understood that the constituent features of the embodiments described herein are merely the most preferred embodiments of the present invention, and are not intended to represent all of the inventive concepts of the present invention, so that various equivalents, And the like. Also, throughout the specification, when an element is referred to as "comprising ", it means that it can include other elements, not excluding other elements, unless specifically stated otherwise.

Hereinafter, the present invention will be described in detail.

<Experimental Method>

1. Experimental material

Peonies used in this experiment were purchased from Onggi Hanbukkuk (Daegu, Korea). Fojye Peony was sprayed with 30% ethanol for 7 minutes at 200 ℃ using a roasting machine (Genesis Co., Ltd., Kyungki-do, Korea). Peanut and mainpox were extracted by heating at 100 ° C for 2 hours and then filtered using a filter paper (Whatman No.2, GE healthcare, Arlington Heights, IL, USA). The filtrate was concentrated under reduced pressure at 50 ° C using a rotary vacuum evaporator (JP / N-1000X, Sunileyela Co., Ltd., Gyeonggido, Korea), lyophilized and stored at -20 ° C.

2. Experimental animals

 Twenty-four male Sprague-Dawley (SD) rats, 7 weeks old, were purchased from Korea Biotech (Chungbuk, Korea) and adapted to the laboratory environment for one week before use in the experiment. The conditions of animal breeding room were controlled by conventional system at temperature of 22 ± 2 ℃, humidity of 50 ± 5% and light cycle of dark cycle for 12 hours. The diets were fed with solid food (Samyang Co., Seoul, Korea) (more than 22.1% of crude protein, 8.0% or less of crude fat, 5.0% or less of crude fiber, 8.0% . The experiment was approved by Daegu Han University Ethical Commission for Animal Experiments (DHU2017-049) and complied with animal management regulations.

3. Reagents

Protease inhibitor mixture, DMSO, Ethylenediaminetetraacetic acid (EDTA), streptozotocin were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan) and the methyl glyoxal solution was purchased from Sigma Aldrich (St Louis, MO, USA). In addition, 2 ', 7'-Dichlorofluorescein diacetate (DCFH-DA) was purchased from Molecular Probes (Eugene, OR, USA) and ECL Western Blotting Detection Reagents was purchased from GE Healthcare (Arlington Height, IL, USA). (PMSF), Collagen, Matrix MetalloProteinase-1 (MMP-1), Histone, and b-actin were purchased from Santa Cruz Biotechnology (Dallas CA, USA) and anti- Ne- (carboxyethyl) (CEL) antibody and polyclonal anti-Ne- (carboxymethyl) lysine (CML), and Receptor for Advanced Glycation End Products (RAGE) antibodies were purchased from COSMO BIO (Tokyo, Japan). Bicinchoninic acid (BCA) protein assay kit for protein determination was purchased from Thermo Scientific (Rockford, IL, USA). Blood urea nitrogen (BUN) assay kit was purchased from Asan Pharmaceutical Co., Ltd. (Hwaseong, Korea).

4. The final glycation product ( AGEs ) cause

Streptozotocin (50 mg / kg) was administered in a single dose to induce AGEs, and 100 mg methyl glyoxal (MGO) was orally administered for 3 weeks after 3 days. The experimental groups were divided into four groups: normal rats (Nor rats), control (AGEs-induced rats; Con) orally administered 100 mM MGO and distilled water at 100 mg / kg, 100 mg / Induced rats treated with 100 mg / kg body weight (PR), 100 mg / kg MGO and 100 mg / kg of Fowaz Peony root extract treated with 100 mg / kg of AGE-induced rats treated with Heated PR 100 mg / kg body weight; HPR).

5. Blood and tissue AGEs  Production amount measurement

After the end of the experiment, blood collected from the abdominal vein was centrifuged at 4,000 rpm for 10 minutes to obtain serum. The skin tissue was disrupted and crushed using 1 mM EDTA-50 mM sodium phosphate buffer (pH 7.4). The amount of AGEs produced in the blood and skin tissues was measured using a rat advanced glycation end products ELISA Kit (cusabio tech, Tokyo, Japan).

6. Oxidative  stress Biomarker  Measure

The ROS value of the oxidative stress biomarker was determined by mixing the serum with 25 mM 2 ', 7'-dichlorofluorescein diacetate (Molecular Probes, Eugene, OR, USA) nm and an excitation wavelength of 485 nm for 30 minutes.

7. Western blotting

To obtain kidney and skin cytoplasm, 100 mM Tris-HCl (pH 7.4), 5 mM Tris-HCl (pH 7.5), 2 mM MgCl ₂ , 15 mM CaCl ₂ , 1.5 M sucrose, 0.1 M DTT and protease inhibitor cocktail After addition of the buffer A, the mixture was pulverized with a tissue grinder (BioSpec Product, Oklahoma, USA) and 10% NP-40 solution was added. The mixture was allowed to stand on ice for 20 minutes and then centrifuged at 12,000 rpm for 2 minutes to separate the supernatant containing cytoplasm. To obtain the nuclei, rinse twice in buffer A supplemented with 10% NP-40 and add 100 mL of buffer C (50 mM HEPES, 50 mM KCl, 0.3 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, ) Was added and resuspended, followed by 3 vortexes every 10 minutes. After centrifugation at 12,000 rpm for 10 min at 4 ° C, the supernatant containing the nuclei was obtained and stored at -80 ° C for freezing. To measure the expression of RAGE, CML, CEL, and b-actin in renal tissue cytoplasm and RAGE, CML, CEL, Collagen, MMP-1, b-actin and Histone protein in skin tissue, After electrophoresis using polyacrylamide gel, acrylamide gel was transferred to nitrocellulose membrane. The membranes were washed with PBS-T 5 times every 6 min. The secondary antibody (1: 3000 in PBS-T) was used for each of the treated primary antibodies. Diluted in PBS) for 1 hour at room temperature, and then washed five times with PBS-T every 6 minutes. After exposing to enhanced chemiluminescence (ECL) solution, the protein was sensitized to Sensi-Q2000 Chemidoc (Lugen Sci Co., Ltd., Seoul, Korea) Program.

8. Statistical Analysis

All values were expressed as mean and standard error. One-way analysis of variance (ANOVA) test was performed using SPSS (Version 22.0, IBM, Armonk, NY, USA) Statistical significance of the mean difference between the groups was verified by p-value <0.05.

<Experimental Results>

1. Serum Oxidative  stress Biomarker  Content measurement

(AGEs) induce cellular reactive oxygen species (ROS) and accelerate intracellular stress by decreasing the activity of glyoxalase, and bind to AGEs receptors on the cell surface by reactive oxygen species, And is reported to be involved in induction. After the end of the experiment, serum collected from the blood of the abdominal vein was centrifuged and the ROS, which is a marker of oxidative stress, was measured.

The results are shown in Fig.

As shown in Fig. 1, the ROS value of the control group (Con) was increased compared to that of the normal group (Nor), and that of the peony extract group (PR) and the peony root extract extract group (HPR) was significantly lower than that of the control group. In particular, it was confirmed that, in the case of the group administered with the peony root extract, the effect was remarkably excellent even when compared with the peony root extract (FIG. 1).

2. In skin tissue AGEs  Production amount measurement

The amount of AGEs produced in the skin tissue was analyzed.

2, the amount of AGEs produced in the control group was significantly increased compared to the normal group. On the other hand, it was found that the PR extract and DPR extract of DPP decreased in comparison with the control. Particularly, in the case of the phytophthora extract-treated group, it was confirmed that the effect was remarkably excellent even when compared with the peony extract, and the results were significant compared with the control group (FIG. 2).

3. In kidney tissue AGEs  On the Expression of Protein

AGEs interact with RAGE and increase oxidative stress by increasing ROS. CML is a representative substance of AGEs and is used as an important index to measure AGE. CEL is chemically similar to CML and is also used as an index to measure AGEs. CEL and CML, AGEs related proteins, were measured in renal tissue.

Referring to FIG. 3, both the CEL and the CML were significantly increased in the control group as compared with the normal group. On the other hand, it was found that the PR extract and DPR extract of DPP decreased in comparison with the control. Especially, it was confirmed that, in the case of the group administered with the peony root extract, the effect was remarkably excellent even when compared with the peony root extract.

4. In skin tissue AGEs  On the Expression of Protein

As shown in FIG. 4, the RAGE, CEL, and CML showed significantly increased levels in the control group as compared with the normal group, as a result of measuring the final glycation product-related proteins CEL, CML, and RAGE. On the other hand, it was found that the PR extract and DPR extract of DPP decreased in comparison with the control. Especially, it was confirmed that, in the case of the group administered with the peony root extract, the effect was remarkably excellent even when compared with the peony root extract.

5. Effect of antioxidant-related protein expression in skin tissue

Active oxygen species (ROS) are an imbalance of the antioxidant system that causes cell damage when overexposed. In addition, it is closely related to various inflammation reaction and skin aging, and it is known that antioxidants suppress oxidative stress and suppress skin collagen reduction. Therefore, antioxidant proteins such as catalase and GPx were measured in the skin tissue of the animals administered with the extract of Ganoderma lucidum.

Referring to FIG. 5, the value of the control group was significantly decreased as compared with that of the normal group. On the other hand, it was found that the extracts of the peony extract (PR) and the peony extract (DP) were increased compared to the control. Especially, it was confirmed that the effect of the extracts of the peony root extract was better than that of the peony root extract.

6. Effect of wrinkle-related protein expression on skin tissue

AGEs are protein glycation products that accumulate in tissues under hyperglycemic conditions, and diabetic patients have been found to have increased levels of endo-glycated products in the body several times over normal subjects. Insulin, which is used in the treatment of diabetes, is associated with the metabolism of binding substances. It has been reported that when insulin treatment is not applied to experimental animals that cause diabetes, AGEs are increased and collagen of skin tissue is decreased. Collagen, a major component of the skin, is a major substrate protein produced by the fibroblasts of the skin. It has functions such as mechanical rigidity of the skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, induction of cell division and differentiation, Is known to be closely related to the formation of wrinkles. The cause of skin wrinkles is to decrease the amount of collagen synthesis or increase the amount of MMPs that break down collagen. Thus, the expression of the wrinkle-related proteins COL1A2 and MMP-1 was observed in the skin of the animals administered with the extract of Oryza sativa.

Referring to FIG. 6A, the level of COL1A2 in the control group was significantly reduced compared to the normal group. On the other hand, it was found that the extracts of the peony extract (PR) and the peony extract (DP) were increased compared to the control. Especially, it was confirmed that the effect of the extracts of the peony root extract was better than that of the peony root extract.

Referring to FIG. 6B, the level of MMP-1 was significantly increased in the control group as compared with the normal group. On the other hand, it was found that the PR extract of DPP and the DPP extract of DPP decreased significantly compared to the control. Especially, it was confirmed that, in the case of the group administered with the peony root extract, the effect was remarkably excellent even when compared with the peony root extract.

While the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, Such modifications and changes are to be considered as falling within the scope of the following claims.

Claims (6)

Paeonia, which inhibits the production of advanced glycation end products and exhibits antioxidant and skin wrinkle-reducing effects, lactiflora extract.
[2] The extract according to claim 1, wherein the extract is one selected from the group consisting of water, an alcohol having 1 to 6 carbon atoms, hexane, ethyl acetate, and a mixed solvent thereof.
The method according to claim 1, wherein the safflower peanut is prepared by wet roasting of peony root in 10 to 70% (v / v) ethanol, followed by roasting at a temperature of 150 to 250 ° C for 3 to 15 minutes Peony root extract.
A composition for antioxidation comprising an extract of a Chinese peony from Chinese cabbage according to any one of claims 1 to 3 as an active ingredient.
A wrinkle-improving food composition comprising the extract of Aesculus foxcorrhoids according to any one of claims 1 to 3 as an active ingredient.
A cosmetic composition for improving wrinkles comprising the extract of Aesculapiana peanuts according to any one of claims 1 to 3 as an active ingredient.

Images